These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro.
    Author: Jaakkola M, Rantanen V, Grénman S, Kulmala J, Grénman R.
    Journal: Anticancer Res; 1997; 17(2A):939-43. PubMed ID: 9137431.
    Abstract:
    In the current study, paclitaxel sensitivity of eight vulvar squamous cell carcinoma (SCC) cell lines was tested using a 96-well plate clonogenic assay. The chemosensitivity was expressed as IC50 corresponding to the drug concentration causing 50% inhibition in clonogenic survival. IC50 values were obtained from dose-response curves after fitting the data to the linear quadratic equation. The paclitaxel sensitivity of the eight vulvar SCC cell lines expressed as IC50 varied from 0.6 to 2.9 nM. The observed differences between the individual cell lines were surprisingly small, only 4.8-fold at the most. Paclitaxel sensitivity of vulvar SCC cell lines is of the same magnitude as the paclitaxel sensitivity of endometrial and ovarian carcinoma cell lines tested in our preliminary experiments with the same assay. We have previously studied the intrinsic radiosensitivity of these vulvar SCC cell lines. No correlation could be found between radiosensitivity and paclitaxel sensitivity. These results indicate that vulvar SCC is consistently sensitive to paclitaxel in vitro. The role of chemotherapy in the treatment of vulvar carcinoma has not been clarified yet. The efficacy of paclitaxel should be tested further in clinical trials.
    [Abstract] [Full Text] [Related] [New Search]